What if you invested $1000 in ILMN on Jan 1, 2020?
Explore hypothetical investment results for stocks, ETFs, and more. See real historical data and share your discoveries.
Historical Annual Returns
Over the past 20 years, Illumina, Inc. has delivered an average annual return of 27.2%. The stock peaked in 2006 with a massive +165.4% gain, while investors faced a downturn in 2011 (-52.6%). Overall, the stock finished in the green 14 times out of 20 years.
Avg Return
+27.2%
Win Rate
70%
14W - 6L
Best
+165.4%
2006
Worst
-52.6%
2011
Performance Consistency
About Illumina, Inc.
Visit Website ↗Illumina, Inc. is an American biotechnology company that specializes in developing, manufacturing, and marketing integrated systems for the analysis of genetic variation and biological function. It operates primarily in the life sciences tools and services sector, focusing on genomic sequencing and array-based solutions that are utilized by a wide range of academic, government, pharmaceutical, biotechnology, and clinical institutions globally.
Key Business Segments
Genomic Sequencing
Provides DNA sequencing platforms and consumables for various applications, including whole-genome sequencing, targeted sequencing, and RNA sequencing.
Microarray Solutions
Offers microarrays for SNP genotyping, gene expression, and protein analysis, providing a cost-effective way to analyze genetic markers.
Kits and Reagents
Develops and supplies a comprehensive range of kits and reagents, including library preparation kits, for diverse DNA and RNA inquiries.
Software and Analysis Tools
Provides a comprehensive bioinformatics suite and software solutions to unlock deeper insights from genetic data.
Key Innovations
- ✓Pioneering and continuously advancing DNA Sequencing Platforms (e.g., NovaSeq, HiSeq, MiSeq, MiniSeq, iSeq, NextSeq) utilizing sophisticated technologies like bridge amplification and reversible terminators.
- ✓Introduction of the NovaSeq X Plus in September 2022, a high-throughput sequencing system capable of sequencing up to 20,000 genomes per year.
- ✓Development of a comprehensive bioinformatics suite and software solutions that facilitate the analysis and interpretation of vast amounts of genetic data.
- ✓Maintaining a dominant position in the genomics market, driven by its next-generation sequencing (NGS) technology.
Historical Milestones
Company founded, laying the groundwork for its leadership in genomics.
Launched the NovaSeq X Plus, significantly advancing high-throughput genomic sequencing capabilities.